Unloxcyt™
Understanding Unloxcyt™
Unloxcyt™ (cosibelimab‑ipdl) is a prescription medicine used to treat adults with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC). Unloxcyt™ may be used to treat CSCC that has spread or cannot be cured by surgery or radiation.
How Unloxcyt™ Works:
- Targeted PD‑L1 pathway inhibition: Unloxcyt™ is a fully human IgG1 monoclonal antibody that binds PD‑L1 and blocks its interaction with PD‑1 and B7.1, restoring anti‑tumor T‑cell activity in the tumor microenvironment.
- Additional immune activity: Unloxcyt™ retains a functional Fc domain and has the potential to engage innate immunity through antibody‑dependent cell‑mediated cytotoxicity (ADCC), which may contribute to tumor cell killing in addition to checkpoint blockade.
FDA Approval:
2024 – Unloxcyt™ (cosibelimab‑ipdl) was approved by the U.S. Food and Drug Administration on December 13, 2024 for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
For more information, please visit the Unloxcyt™ patient website. Speak with your healthcare provider to determine if Unloxcyt™ is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: Checkpoint Therapeutics, Inc. and Sun Pharmaceutical Industries |
CLASS: PD‑L1 blocking monoclonal antibody (immune checkpoint inhibitor) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: Intravenously As An Infusion |
|
FREQUENCY: Once every 3 weeks |
Length of infusion: 60 minutes |
FOR MORE INFORMATION: |
